|
1. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA and Pao W. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 12, 6494-6501.
2. Bianco R, Troiani T, Tortora G and Ciardiello F. (2005). Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocrine-Related Cancer. 12 Suppl 1, S159-S171.
3. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE and Ellis LM. (2005). Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 11, 397-405.
4. de Melker AA, van der Horst G and Borst J. (2004). c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. J Cell Sci. 117, 5001-5012.
5. Dikic I and Giordano S. (2003). Negative receptor signalling. Curr Opin Cell Biol. 15, 128-135.
6. Giaccone G. (2000). Clinical perspectives on platinum resistance. Drugs. 59 Suppl 4, 9-17.
7. Goh LK, Huang F, Kim W, Gygi S and Sorkin A. (2010). Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol. 189, 871-883.
8. Haak-Frendscho M, Kino K, Sone T and Jardieu P. (1993). Ling Zhi-8: a novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. Cell Immunol. 150, 101-113.
9. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M and Franklin WA. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 41 Suppl 1, S29-S42.
10. Hu H, Ahn NS, Yang X, Lee YS and Kang KS. (2002). Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 102, 250-253.
11. Inamura K, Ninomiya H, Ishikawa Y and Matsubara O. (2010). Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 134, 66-72.
12. Jiang J, Slivova V, Valachovicova T, Harvey K and Sliva D. (2004). Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol. 24, 1093-1099.
13. Kafri T, van Praag H, Ouyang L, Gage FH and Verma IM. (1999). A packaging cell line for lentivirus vectors. J Virol. 73, 576-584. 14. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K and Tsunoo H. (1989). Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem. 264, 472-478.
15. Koberle B, Tomicic MT, Usanova S, Kaina B. (2010). Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta. 1806, 172-182.
16. Liang C, Li H, Zhou H, Zhang S, Liu Z, Zhou Q and Sun F. (2012). Recombinant LZ-8 from Ganoderma lucidum induces endoplasmic reticulum stress-mediated autophagic cell death in SGC-7901 human gastric cancer cells. Oncol Rep. 4, 1079-1089.
17. Lin ZB and Zhang HN. (2004). Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin. 25, 1387-1395.
18. Marmor MD and Yarden Y. (2004). Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 23, 2057-2070.
19. Miyoshi H, Blömer U, Takahashi M, Gage FH and Verma IM. (1998). Development of a self-inactivating lentivirus vector. J Virol. 72, 8150-8157.
20. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J and Yarden Y. (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem. 278, 21323-21326. 21. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM and Trono D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272, 263-267.
22. Nguyen KS, Kobayashi S and Costa DB. (2009). Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 10, 281-289.
23. Nicholson, R.I., Gee, J.M., and Harper, M.E. (2001). EGFR and cancer prognosis. Eur J Cancer. 4, 9-15.
24. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S and Kikuchi K. (2000). Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancerpatients with p53 overexpression. Oncol Rep. 7, 603-607.
25. Oksvold MP, Thien CB, Widerberg J, Chantry A, Huitfeldt HS and Langdon WY. (2003). Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene. 22, 8509-8518.
26. Ozols RF. (1991). Ovarian cancer: new clinical approaches. Cancer Treat Rev. 18 Suppl A, 77-83.
27. Paterson RR. (2006). Ganoderma a therapeutic fungal biofactory. Phytochemistry. 67, 1985-2001.
28. Scagliotti GV, Selvaggi G, Novello S and Hirsch FR. (2004). The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 10, 4227-4232.
29. Siegel R, Naishadham D and Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin. 63, 11-30.
30. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP and Polo S. (2005). Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA. 102, 2760-2765.
31. Sliva D. (2006). Ganoderma lucidum in cancer research. Leuk Res. 30, 767-768.
32. Sorkin A and Von Zastrow M. (2002). Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol. 3, 600-614.
33. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC and Salgia R. (2010). CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 5, e8972.
34. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, Sakuma S and Tsunoo H. (1989). Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidium, having similarity to immunoglobulin variable regions. J Biol Chem. 264, 16372-16377.
35. van der Hem LG, van der Vliet JA, Bocken CF, Kino K, Hoitsma AJ and Tax WJ. (1995). Ling Zhi-8: studies of a new immunomodulating agent. Transplantation. 60, 438-443.
36. Veale D, Kerr N, Gibson GJ, Kelly PJ and Harris AL. (1993). The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 68, 162-165.
37. Volm M, Rittgen W and Drings P. (1998). Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 77, 663-669.
38. Weng CJ, Chau CF, Yen GC, Liao JW, Chen DH and Chen KD. (2009). Inhibitory effects of ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models. J Agric Food Chem. 57, 5049-5057.
39. Wu CT, Lin TY, Hsu HY, Sheu F, Ho CM and Chen EI. (2011). Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis. 12, 1890-1896.
40. Xu Z, Hang J, Hu J and Gao B. (2014). Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells. J BUON. 19, 466-473. 41. Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J and Samelson LE. (2002). Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci. 115, 1791-1802.
42. Yarden Y and Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2, 127-137.
43. Yun TK. (1999). Update from Asia. Asian studies on cancer chemoprevention. Ann N Y Acad Sci. 889, 157-192.
|